3-D mapping biopsy better than ultrasound-guided biopsy for prostate cancer

Ultrasound-guided biopsies miss prostate cancers that can be detected by the slightly more expensive and slightly more invasive 3D mapping biopsies. For example, in a 2006 study of 180 men diagnosed with early stage prostate cancer via ultrasound-guided biopsy, nearly a quarter were upgraded to a more clinically significant stage of disease after 3D mapping biopsy found pockets of cancer that the first technique had missed.

Now, a new study reports the locations of these most frequently missed pockets of prostate cancer (Krughoff K et al. The accuracy of prostate cancer localization diagnosed on transrectal ultrasound-guided biopsy compared to 3-dimensional transperineal approach Adv Urol. 2013; 249080). There are three major reasons for carrying out 3D mapping biopsies in the clinic. First, a man may have rising PSA despite a series of negative biopsies and so want a more detailed opinion. Secondly, a man may prefer additional reassurance that watching and waiting is the best course of action rather than treatment. Thirdly, a man may pursue focal therapy in which only the cancerous sections of the prostate are removed and so needs accurate information on the position of his cancer, according to Dr Al Barqawi, investigator at the Colorado University Cancer Center and the paper’s senior author. Dr Barqawi is a pioneer of the 3D mapping biopsy technique, in which needle biopsies are taken 5mm apart across the x, y and z axes of a three-dimensional grid through the prostate. He has performed over 600 procedures. The most recent study enrolled 161 men who had been diagnosed with low-stage prostate cancer by ultrasound-guided biopsy. The study involved performing 3D mapping biopsies at an average  of 192 days after the first biopsy and compared the results. Overall, ultrasound-guided biopsy found an average of 1.38 cancerous zones per patient, whereas 3D mapping biopsy found nearly three times the number of positive zones, namely 3.33 per patient. The follow-up findings from the 3D mapping study resulted in upgrading the severity of many of these seemingly low-grade cancers. “But we already knew that 3D mapping was likely to upgrade a prostate cancer’s Gleason score,” Barqawi says. “What we hoped to discover in this study is exactly where cancer is being missed by ultrasound-guided biopsy.”

Of these 161 total cases, cancer was found in the left-mid section of the prostate 62 times after it had been missed by ultrasound-guided biopsy. Likewise, 3D mapping found 62 unreported cancers in the right-mid section and 41 undetected cancers in the left-apex zone.

“This study adds to our knowledge about the interface and best uses of these two techniques. The cost and invasiveness of 3D mapping biopsy make it inappropriate for screening, but our message is that with the confirmation or strong suspicion of cancer, 3D mapping biopsy offers a much more accurate assessment of the location, stage and risk” Barqawi says.